|
Status
|
Topic selection
|
|
Technology type
|
Medicine
|
|
Decision
|
Not selected
|
|
Reason for decision
|
Not eligible for Health Technology Evaluation guidance
|
|
Further information
|
It has been concluded that this licence extension will be incorporated into the Multi-Technology Appraisal of Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]. For more information on ID3834, please email TATeam5@nice.org.uk.
|
| ID number |
10767
|
Project Team
| Project lead |
Abigail Stephens |
Email enquiries
For further information on how we select topics for development, please see our page about topic selection